Acamprosate
Campral (acamprosate) is a small molecule pharmaceutical. Acamprosate was first approved as Campral on 2004-07-29. It is used to treat alcoholism in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Acamprosate calcium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CAMPRAL | Forest Laboratories | N-021431 DISCN | 2004-07-29 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| acamprosate calcium | ANDA | 2022-11-17 |
| campral | New Drug Application | 2016-08-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| alcoholism | EFO_0003829 | D000437 | F10.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
777 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 5 | 10 | 17 | 15 | 14 | 58 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 4 | 9 | 15 | 13 | 5 | 43 |
| Cerebral palsy | D002547 | G80 | 2 | 7 | 13 | 4 | 11 | 35 | |
| Muscle spasticity | D009128 | HP_0001257 | 1 | 5 | 11 | 8 | 10 | 35 | |
| Torticollis | D014103 | HP_0000473 | F45.8 | 4 | 8 | 10 | 7 | 5 | 32 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 2 | 5 | 9 | 7 | 6 | 27 |
| Urinary incontinence | D014549 | HP_0000020 | R32 | 1 | 4 | 10 | 5 | 5 | 24 |
| Urge urinary incontinence | D053202 | EFO_0006865 | N39.41 | 3 | 2 | 5 | 4 | 2 | 14 |
| Hyperhidrosis | D006945 | HP_0000975 | 3 | 2 | 2 | 4 | 3 | 14 | |
| Blepharospasm | D001764 | G24.5 | 1 | 3 | 5 | 4 | 2 | 13 |
Show 69 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tennis elbow | D013716 | EFO_1001896 | M77.1 | — | — | 4 | — | 3 | 7 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | 1 | 2 | 2 | — | 1 | 6 | |
| Sialorrhea | D012798 | HP_0002307 | K11.7 | — | 5 | 3 | — | 1 | 6 |
| Plantar fasciitis | D036981 | EFO_1001909 | M72.2 | — | 3 | 2 | — | 2 | 5 |
| Temporomandibular joint disorders | D013705 | M26.6 | 1 | 2 | 2 | — | 1 | 5 | |
| Vulvodynia | D056650 | N94.81 | — | 1 | 3 | — | — | 4 | |
| Headache | D006261 | HP_0002315 | R51 | — | — | 2 | — | 2 | 4 |
| Dystonic disorders | D020821 | G24 | — | 1 | 1 | — | 2 | 3 | |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | 3 | 2 | — | — | 3 |
| Cluster headache | D003027 | HP_0012199 | G44.00 | 2 | 2 | 1 | — | — | 3 |
Show 25 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lower urinary tract symptoms | D059411 | EFO_0008008 | 1 | 1 | — | — | 1 | 3 | |
| Smiling | D012904 | — | 1 | — | — | 1 | 2 | ||
| Abdominal hernia | D046449 | K46 | — | 1 | — | — | 1 | 2 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | — | — | — | 2 |
| Tendinopathy | D052256 | EFO_1001434 | M77.9 | — | 2 | — | — | — | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | — | 1 | 2 |
| Back pain | D001416 | HP_0003418 | M54 | — | 1 | — | — | 1 | 2 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | 2 | — | — | — | 2 |
| Neck pain | D019547 | HP_0030833 | M54.2 | 1 | 1 | — | — | 1 | 2 |
| Contracture | D003286 | EFO_0003899 | M62.4 | — | 1 | — | — | 1 | 2 |
Show 43 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 2 | — | — | — | — | 2 |
| Hemorrhagic stroke | D000083302 | 1 | — | — | — | — | 1 | ||
| Internal carotid artery dissection | D020215 | 1 | — | — | — | — | 1 | ||
| Vertebral artery dissection | D020217 | I77.74 | 1 | — | — | — | — | 1 | |
| Myelodysplastic syndromes | D009190 | D46 | 1 | — | — | — | — | 1 | |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | — | — | — | — | 1 | |
| Gingival overgrowth | D019214 | K06.1 | 1 | — | — | — | — | 1 | |
| Treatment-resistant depressive disorder | D061218 | 1 | — | — | — | — | 1 | ||
| Complex regional pain syndromes | D020918 | EFO_1001998 | 1 | — | — | — | — | 1 | |
| Secondary headache disorders | D051271 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Strabismus | D013285 | HP_0000486 | H50.2 | — | — | — | — | 2 | 2 |
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | — | — | — | 2 | 2 |
| Constipation | D003248 | HP_0002019 | K59.0 | — | — | — | — | 2 | 2 |
| Treatment outcome | D016896 | — | — | — | — | 1 | 1 | ||
| Dystonia | D004421 | HP_0001332 | G24 | — | — | — | — | 1 | 1 |
| Skin abnormalities | D012868 | HP_0000951 | Q82.9 | — | — | — | — | 1 | 1 |
| Muscle tonus | D009129 | — | — | — | — | 1 | 1 | ||
| Physical therapy modalities | D026741 | — | — | — | — | 1 | 1 | ||
| Dysphonia | D055154 | R49.0 | — | — | — | — | 1 | 1 | |
| Urologic diseases | D014570 | N39.9 | — | — | — | — | 1 | 1 |
Show 22 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ACAMPROSATE |
| INN | acamprosate |
| Description | Acamprosate is an organosulfonic acid that is propane-1-sulfonic acid substituted by an acetylamino group at position 3. It has a role as a neurotransmitter agent, an environmental contaminant and a xenobiotic. It is an organosulfonic acid and a member of acetamides. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)NCCCS(=O)(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 77337-76-9 |
| RxCUI | 82819 |
| ChEMBL ID | CHEMBL1201293 |
| ChEBI ID | 51041 |
| PubChem CID | 71158 |
| DrugBank | DB00659 |
| UNII ID | N4K14YGM3J (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,211 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,991 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more